<DOC>
	<DOCNO>NCT02378428</DOCNO>
	<brief_summary>This Phase II study patient MIBG avid tumor . The study determine response rate &lt; 131 &gt; I-MIBG patient de novo , relapse refractory neuroblastoma MIBG avid malignant tumor 42 day post MIBG therapy . It also evaluate tolerability safety study agent evaluate hematopoietic non-hematopoietic toxicity &lt; 131 &gt; I-MIBG therapy . Tumor response evaluate compare patient 's disease pre-treatment patient 's day +42 post &lt; 131 &gt; I-MIBG treatment . The evaluation may include follow : &lt; 131 &gt; I-MIBG scan , CT MRI , urine catecholamine , bone marrow analyse test consider standard care cancer evaluation . To eligible participation , patient must tumors MIBG avid . Patients must also stem cell source autologous rescue event protract therapy associate cytopenia . Peripheral stem cell collection prefer hematopoietic cell source . Bone marrow harvest hematopoietic cell source alternative . This study provide data future clinical trial utilize &lt; 131 &gt; I-MIBG therapy . A room H12 prepared lead line wall , many radiation safety component accomodate treatment . &lt; 131 &gt; I metaiodobenzlguanidine ( &lt; 131 &gt; I-MIBG ) radiopharmaceutical concentrate within adrenomedullary tissue . The agent initially use tumor image due capability locate pheochromocytoma , neuroblastomas neuroendocrine tumor . &lt; 131 &gt; I-MIBG subsequently use therapeutic agent tumor type . Phase I II therapeutic trial target neuroblastoma report response rate 10-50 % . Toxicities observe mainly hematopoietic , ~50 % patient receive 15mCi/kg require stem cell reinfusion . Observed non-hematopoietic toxicity mild . Most recently , trial conduct combine study agent myeloablative chemotherapy stem cell reinfusion perform initial response rate ~50 % .</brief_summary>
	<brief_title>MIBG Therapy Patients With MIBG Avid Tumors</brief_title>
	<detailed_description />
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Diagnosis : diagnosis neuroblastoma time relapse histology and/or demonstration clump tumor cell bone marrow elevate urinary catecholamine metabolite Disease Status : The presence refractory progressive disease ( PD ) The presence mixed response ( MR ) , response ( NR ) follow completion A3973 equivalent induction therapy , presence partial response ( PR ) high Curie score ( &gt; 2 ) follow induction therapy . Patients de novo high risk neuroblastoma complete standard induction therapy achieve CR , VGPR , PR low Curie score post induction . Patients must evidence MIBG avid disease determine diagnostic MIBG scan obtain within 4 week study entry . Performance Level Life Expectancy : Patients must Lansky Play Scale17 60 % ( &lt; 16 yrs old ) , Karnofsky score 60 % ( &gt; 16 yrs old ) , ECOG score &lt; equal 2 life expectancy 2 month . Pregnancy breast feed Have undergone prior allogeneic BMT . Patients disease major organ system would compromise ability withstand therapy . Any significant organ impairment discuss Study Chair prior patient entry . Patients hemodialysis . Hepatitis B surface antigen ( + ) Hepatitis C positive precede six month . Patients active infection require intravenous antiviral , antibiotic antifungal . Patients prolonged antifungal therapy still eligible culture negative biopsy negative suspect residual radiographic lesion stabilize regressed meet organ function criterion . Prior total body irradiation , prior total abdominal whole liver radiation Any medical psychological condition situation deem PI put patient increase risk complication noncompliance . Patients curative treatment option . Patients busulfan/ melphalan consolidation therapy follow treatment 131IMIBG plan . Patients CEM ( carboplatin , etoposide , melphalan ) therapy administer within 30 day prior 131IMIBG therapy therapy plan within 30 day follow administration 131IMIBG . Patients know MIBG avid brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuroblastoma</keyword>
</DOC>